February 4, 2022
Eisai racked up double-digit growth in its April-December revenue and profits on the back of buoyant sales of its cancer drug Lenvima (lenvatinib) and an upfront payment earned under its antibody drug conjugate (ADC) deal with Bristol Myers Squibb. In...read more